Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
Akanda Corp. (NASDAQ:AKAN) will supply Tetra Bio-Pharma (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEF and related products.
阿寒田 (納斯達克:阿寒) 將供應利特拉生物製藥 (框架:果醬 1) (TSX: TBP) (框架:果醬 1) 由于, 醫藥級, 大麻, 花 以微劑量帽形式，用於 斯托茨 & 雙克爾強大的軍醫汽化器 用於 Tetra 的全球商業化 齊克勒夫 和相關產品。
In addition, Akanda will act as a contract development and manufacturing organization (CDMO) for Tetra's clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in addition to being an EU GMP cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company.
此外，阿肯田將充當c發生 d發展及 米製造 oRganization CDMO）用於 Tetra 的臨床藥物和商業供應計劃。通過這個項目，阿坎達除了成為歐盟 GMP 大麻製造商外，還成為 CDMO，這標誌著阿坎達的第一家 進入大麻素藥物開發對於公司來說，這是一個新的和不斷增長的市場機會。
QIXLEEF is a proprietary botanical inhaled investigational new drug currently being studied in two U.S. Food and Drug Administration authorized clinical trials: 1) REBORN 1, a Phase 2 study authorized by the FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain, and 2) PLENITUDE, a Phase 2 multicenter clinical trial authorized by the FDA to evaluate the safety and efficacy of inhaled cannabinoids to relieve uncontrolled pain in patients with advanced cancer.
QIXLEEF 是一項專有的植物吸入研究新藥，目前正在美國食品和藥物管理局授權的兩項臨床試驗中研究：1）REBORN 1，FDA 授權用於評估吸入大麻素對一類立即釋放口服阿片類藥物用於突破性癌症疼痛管理的 2 期研究，以及 2）PLENITUDY，經 FDA 授權的多中心試驗和評估安全性的 2 期臨床療效吸入大麻素以減輕晚期癌症患者不受控制的疼痛。
Under the multi-year agreement, Akanda will supply Tetra with quality, premium THC and CBD flower, and will provide regulatory, quality and pharmaceutical manufacturing services for the QIXLEEF clinical drug development and marketing authorization from its Portugal operations.
根據多年的協議，Akanda 將為 Tetra 提供優質、優質的 THC 和 CBD 花卉，並將為其葡萄牙業務的 QIXLEEF 臨床藥物開發和市場授權提供監管、品質和藥品製造服務。
"This supply agreement with Tetra is a major milestone in Akanda's journey in becoming a cannabis platform company serving all regulated markets in the EMEA region," stated Tej Virk, CEO of Akanda. "In supporting a terrific partner with a mission to improve patient health and quality of life though cannabinoid-derived medicine, we are demonstrating that cannabis can fit into the traditional public sector model, with the expectation of reimbursement. Simultaneously, we are productively utilizing our diverse capabilities to support clinical trials for pharma grade cannabinoids. If approved, we expect to provide flower for the authorized compound, potentially creating a significant, incremental revenue stream for Akanda. This opportunity could only have been possible with our state-of-the-art facilities that we gained through the acquisition of Holigen in May."
「與 Tetra 簽訂的這項供應協議是 Akanda 成為服務歐洲、中東和非洲地區所有受監管市場的大麻平台公司的重要里程碑。」 特 J 維克，阿坎達的首席執行官。「在支持一個了不起的合作夥伴，其使命是改善患者的健康和生活質量，儘管大麻衍生的藥物，我們證明了大麻可以適應傳統的公共部門模型，並期望報銷。同時，我們有效地利用我們的多元化能力來支持製藥級大麻素的臨床試驗。如果獲得批准，我們預計將為授權化合物提供鮮花，從而為 Akanda 創造顯著的增加收入來源。只有我們在 5 月份收購 Holigen 獲得的最先進設施才能實現這一機會。」
Meet Akanda's CEO Tej Virk and a slew of other cannabis execs, entrepreneurs, CEOs, investors, etc. at the September Benzinga Cannabis Capital Conference, Sept. 13-14 in Chicago. Get your tickets HERE and reserve your spot at the Palmer House Hotel HERE.
見面 阿田 執行長 特 J 維克 在 9 月 13-14 日在芝加哥舉行的 9 月 Beninga 大麻資本會議上，還有許多其他大麻高管，企業家，首席執行官，投資者等。在這裡獲取門票，並在帕爾默之家酒店預訂您的位置。
Photo: Courtesy of Business Wire
相片：由美國商業資訊提供
Related News
相關消息
Akanda's CanMart Partners With Phlo Connect And Cellen Life Sciences To Strengthen Its Position In UK Medical Cannabis Market
阿坎達的 CanMart 與 Phlo Connect 和 Cellen 生命科學合作，加強其在英國醫療大麻市場的地位
The Flowr Corp. Revenue Grows 64% In 2021, Achieves Record Quarterly Revenue Thanks To This
Flowr 公司收入在 2021 年增長了 64％，由於這一季度營收創紀錄
Halo Collective Q1 2022 Revenue Slightly Drops, Announces Significant Reductions
光環集體 2022 年第一季度營收略有下降，宣布大幅減少
譯文內容由第三人軟體翻譯。